Table 1. Baseline characteristics of patients included according to treatment arm.

Variable	Response Category	Arm1 gemcitabine alone (N = 49)		Arm 2 FOLFIRI.3 + gemcitabine (N = 49)
		N	%	N	%
Sex	male	28	57.1	31	63.3
	female	21	42.9	18	36.7
WHO performance status	0	16	32.6	16	32.7
	1	33	67.4	33	67.3
Previous surgery	no	40	81.6	38	77.6
	yes	9	18.4	11	22.4
Surgery type	curative	4	8.2	5	10.2
	palliative	5	10.2	5	10.2
	not applicable	40	81.6	38	77.6
	missing	0	0.0	1	2.0
Number of metastatic sites	1	35	71.4	33	67.3
	more than 1	14	28.6	16	32.7
Previous chemotherapy	no	40	81.6	44	89.8
	yes	3	6.1	2	4.1
	missing	6	12.2	3	6.1
Primary tumor location	head	29	59.2	18	36.7
	body	11	22.5	17	34.7
	tail	12	24.5	17	34.7
Sites of metastasis	liver	35	71.4	39	79.6
	lung	11	22.5	11	22.5
	lymph node	7	14.3	5	10.2
	peritoneal	10	20.4	16	33.7
	other	2	4.0	3	6.1
Age (years) a		45	63 [41–76]	48	62 [38–76]
Leukocytes (/mm3) a		49	7600 [3100–36500]	49	8300 [85–21700]
neutrophils (/mm3) a		49	5000 [1800–32850]	48	5591.5 [2300–19530]
Creatinine (μmol/l) a		48	71.0 [39–105]	48	70 [45–108]
Glycaemia (mmol/l) a		29	6.2 [4.1–14]	25	5.8 [0.7–15]
Bilirubin (μmol/l) a		48	11.6 [4–227]	45	12 [1–154]
LDH (UI/L) a		23	271 [96–5022]	22	340.5 [133–766]
Hemoglobin (g/dl) a		49	12.8 [7.9–16.5]	48	12.9 [9.4–16]
Platelet (10^3/mm3) a		49	239 [94–570]	48	278.5 [111–634]
ASAT (UI/L) a		49	26 [8–149]	46	41.5 [10–187]
ALAT(UI/L) a		49	35 [8–155]	46	53.5 [10–348]
Prothrombin (%) a		39	93 [26–109]	41	86 [19–122]

^aMedian [min-max] for continuous variables.